1.1Ginger powder for cramps
The manufacturer mills dried ginger rhizome and fills hard capsules with measured portions of powder. The capsule shell dissolves after swallowing and releases the powder into the gastrointestinal tract.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The manufacturer mills dried ginger rhizome and fills hard capsules with measured portions of powder. The capsule shell dissolves after swallowing and releases the powder into the gastrointestinal tract.
The manufacturer measures the caffeine concentration of the dry extract and adjusts the capsule fill mass to deliver a consistent amount per serving. Caffeine blocks adenosine receptors and increases alertness.
The manufacturer blends calcium citrate with microcrystalline cellulose and compresses the blend into tablets. Each serving contains a specified mass of elemental calcium, which the tablets release as they disintegrate in the gastrointestinal tract.
A hard capsule contains ferrous bisglycinate and a cellulose filler. The fill mass is set by the elemental iron content, and the capsule disintegrates after swallowing to release iron for intestinal absorption.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A food quality laboratory prepares three solid reference blends containing clove and immortelle, theacrine and broccoli, and palmitoylethanolamide and ancient peat, respectively. Each blend is mixed with powdered cellulose and sealed in individually labeled vials. Analysts weigh an aliquot from each vial into a separate extraction tube and run it alongside a cellulose blank to monitor repeatability during sample preparation.
The second composition uses milled broccoli seed powder in place of broccoli floret powder and retains theacrine. The seed powder is sieved, premixed with theacrine by geometric dilution, and filled into hard capsules. The clove and immortelle blend and the palmitoylethanolamide and ancient peat blend are filled into separate capsules.
A size 00 outer capsule holds two sealed size 5 inner capsules and loose powder in the space around them. One inner capsule contains clove and immortelle, the other contains theacrine and broccoli, and the loose powder contains palmitoylethanolamide and ancient peat. The assembled unit is swallowed once, and the outer shell opens in aqueous fluid to release the loose powder and expose both inner shells.
A blister card holds oral units containing clove and immortelle, theacrine and broccoli, and palmitoylethanolamide and ancient peat in three labeled rows. A two-dimensional code on the card encodes the package identifier, lot number, and expiration date. A handheld scanner reads the code into a pharmacy inventory system, which tracks card counts by lot and lists stock in expiration order.
A mobile calendar stores the user’s reported period start dates and a selectable reminder window for each of the three oral compositions. The software calculates cycle day from the latest reported start date and schedules local notifications for the enabled windows. Each notification displays the selected composition’s ingredient pair and lets the user record whether they took the unit.
Three gravimetric feeders hold the clove and immortelle blend, the theacrine and broccoli blend, and the palmitoylethanolamide and ancient peat blend. A programmable controller runs each feeder until its load cell measures the target mass loss, depositing each blend into its own sachet lane. A downstream checkweigher compares sealed sachet weights against lane-specific limits and diverts units outside those limits for inspection.
The manufacturer mills dried clove buds and blends the powder with spray-dried immortelle flower extract. A hard cellulose capsule holds a measured portion of the blend.
The manufacturer dry blends crystalline theacrine with freeze-dried broccoli floret powder and compacts the blend into ribbons. The ribbons are milled and sieved into granules for capsule filling.
The manufacturer blends micronized palmitoylethanolamide with a dried extract prepared from ancient peat and adds microcrystalline cellulose as a filler. The blend is filled into hard capsules by weight.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In a particular embodiment, the composition includes a broccoli extract in combination with a composition including Hibiscus flower extract, Ferula Assa Foetida root extract, pear fruit extract, and green tea leaf extract, which exhibit a synergistic effect in protecting the skin from the adverse effects of ultraviolet radiation.A · US 2009/0324522 A1 · abstract
In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1.B · US 2021/0060047 A1 · abstract
An empty cell means only that no passage was reproduced there.
This invention relates to topical antioxidant compositions for the protection and treatment of human skin, particularly skin exposed to harmful ultraviolet radiation.A · US 2009/0324522 A1 · ¶ 3
Since sunscreens are unable to completely protect the skin against the adverse effects of ultraviolet radiation, alternative modes of protection have been proposed.A · US 2009/0324522 A1 · ¶ 10
For these reasons, the medical field currently dedicates growing attention to the problems of the complex Neuro-Immuno-Vascular Peripheral System, especially—even if not exclusively—at the level of arterial vessels.B · US 2021/0060047 A1 · ¶ 3
This acute and chronic neuroimmune response is an important risk factor in vascular remodeling processes.B · US 2021/0060047 A1 · ¶ 6
patent.fyi, US 2026/0355271 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355271/, SHA-256 ccfd73e3b42732f59a8edb6400d80f6a81af4e53f93abf3cce1d4caf9a096ef0